Mr. Tony O'Brien:

Yes, in accuracy as well, particularly as the test is not 100% accurate. The laboratories are all operating within the norms one would expect, and this is monitored closely.

Regarding the alert system, the first thing to note is that the CervicalCheck programme will be fully data-linked with the National Cancer Registry. The triggering of a review will be based either on a notification from the registry or, where that notification becomes known to the programme more quickly, as a result of presentation at one of the colposcopy clinics. Each individual review will be undertaken expeditiously and the information communicated at speed to the treating clinician. The treating clinician will be the one to convey that information to each individual patient. We will go through a specific learning exercise and a review of what happened in this particular case to ensure that we cover and block off the gaps. There will, of course, be continuous sharing of information at appropriate times with the Department of Health, just as there was in this instance but perhaps in a different way, more efficiently and more transparently. Of course, what we will not allow to happen again is the kind of confusion and communication that arose in respect of this cohort, the numbers of women who had assessments carried out versus the National Cancer Registry data, which I discussed in my opening statement.